Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 2/20 | 0.39 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18997317 | 0.81 | KMT2A (0.42) | RXFP1LMNAALDH1A1MAPK1MEN1 | |
| SCHEMBL16589301 | 0.78 | RAPGEF4 (0.36) | ALDH1A1MEN1KMT2A | |
| SCHEMBL15616926 | 0.76 | BRD4 (0.47) | XPO1RXFP1 | |
| SCHEMBL15616944 | 0.73 | RXFP1 (0.42) | XPO1RXFP1MAPTLMNAALDH1A1 | |
| SCHEMBL25745842 | 0.69 | TYR (0.40) | XPO1RXFP1MAPTLMNAALDH1A1 | |
| SCHEMBL24565768 | 0.68 | BRD4 (0.45) | XPO1RXFP1LMNAALDH1A1MAPK1 | |
| SCHEMBL10460879 | 0.67 | L3MBTL1 (0.40) | XPO1RXFP1LMNAALDH1A1MAPK1 | |
| SCHEMBL24007756 | 0.66 | ALDH1A1 (0.41) | RXFP1MAPTLMNAALDH1A1MAPK1 | |
| SCHEMBL23957950 | 0.65 | MEN1 (0.37) | MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL16019374 | 0.65 | CA2 (0.39) | KRASSOS1RXFP1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | XPO1 1855/4885KRAS 608/4885SOS1 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.